Commentary on “Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicenter, open-label, randomized controlled trial.” Bleeding Thromb Vascul Biol. 2024;3(2). doi:10.4081/btvb.2024.141